華仁藥業(300110.SZ):擬收購廣西裕源及浦北新科各100%股權
格隆匯 10 月 26日丨華仁藥業(300110.SZ)公佈,2020年10月26日,公司與此次收購交易對方簽署《關於廣西裕源藥業有限公司100%股權、浦北縣新科藥品包裝有限公司100%股權之股權轉讓協議》,公司以自有資金38503.83萬元收購交易對方所持有廣西裕源藥業有限公司100%股權、浦北縣新科藥品包裝有限公司100%股權。其中,廣西裕源100%股權的交易價格為3.82億元,浦北新科100%股權的交易價格為303.83萬元。
浦北新科2019年、2020年1-5月份的淨利潤分別為-96.44萬元、-160.43萬元。浦北新科是裕源藥業的上游配套企業,為裕源藥業大輸液生產提供塑料包裝製品,兩公司位於同一廠區,此次收購是將裕源藥業和浦北新科作為一個整體進行收購,裕源藥業2019年、2020年1-5月份的淨利潤分別為2113.09萬元、516.33萬元。
公司此次股權收購,是在國家深入推進醫療衞生體制改革和藥品採購制度改革的背景下實施的,是為了積極響應國家“健康中國”戰略,充分發揮公司“國企控股+上市公司+金融賦能”的平台優勢,抓住行業洗牌帶來的市場機遇。裕源藥業作為西南地區專業大輸液生產企業,在產品品種和品規、品牌及市場、成本控制、地理區位等方面,具備一定的優勢,與本公司具有較強的協同效應。公司目前大輸液產品以非PVC軟袋等高端產品為主,裕源藥業目前產品以直立軟袋、塑瓶、玻璃瓶等產品為主,此次收購後,能夠快速補齊公司的大輸液品種和品規,與公司現有品種和產線相互結合,形成公司輸液產品高中低檔全覆蓋的產品結構,降低生產成本,拓展銷售渠道,充分發揮協同效應,實現規模效益,為公司產品力建設、產業佈局延伸和資源配置優化做好支撐,推動主營業務快速穩定發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.